Japan’s Ministry of Health, Labour and Welfare approved Moderna’s COVID-19 vaccine
On May 21, 2021, Moderna announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan granted…
Ministry of Food and Drug Safety of South Korea authorized Moderna’s COVID-19 vaccine
On May 21, 2021, Moderna announced that the Ministry of Food and Drug Safety of South Korea (MFDS)…
Complete trial results of Novavax COVID-19 investigational vaccine posted to preprint server medRxiv
On May 21, 2021, Novavax announced that the full results from the Phase 3, randomized, observer-blinded, placebo-controlled trial…
Novavax announced participation in mix-and-match COVID-19 vaccine booster trial in the United Kingdom
On May 21, 2021, Novavax announced participation in a mix-and-match (vaccine interchangeability) COVID-19 vaccine booster trial that led…
Moderna announced new supply agreement with Australia for 25 million doses of its COVID-19 vaccine
On May 12, 2021, Moderna announced a new supply agreement with the government of Australia for 25 million…
Novavax announced positive preclinical data for combination influenza and COVID-19 vaccine candidate
On May 10, 2021, Novavax announced data from a preclinical study of the company’s combination quadrivalent seasonal flu…
INOVIO announced positive data from phase 2 clinical trial evaluating INO-4800 COVID-19 DNA vaccine
On May 10, 2021, Inovio Pharma announced positive safety, tolerability and immunogenicity data from its placebo-controlled and blinded…
Moderna announced agreement with Switzerland for 7 million booster vaccine doses in 2022 with options
On May 6, 2021, Moderna announced a new supply agreement with the Swiss Federal Government for 7 million…
Novavax and Gavi executed advance purchase agreement for COVID-19 vaccine for COVAX facility
On May 6, 2021, Novavax announced that it had finalized an advance purchase agreement (APA) with Gavi, the…
Moderna announced positive initial booster data against SARS-CoV-2 variants
On May 5, 2021, Moderna announced initial data from its Phase 2 study showing that a single 50…
NEJM published phase 2b clinical trial results demonstrating efficacy of COVID-19 vaccine against B.1.351 variant
On May 5, 2021, Novavax announced the publication of results from the initial primary analysis of a Phase…
Pfizer and BioNTech received Health Canada authorization of COVID-19 vaccine in adolescents
On May 5, 2021, Pfizer and BioNTech announced that Health Canada had expanded the Interim Order authorization for…
Hoth Therapeutics and Virginia Commonwealth University expanded research agreement for COVID-19 therapeutic
On May 5, 2021, Hoth Therapeutics announced it has expanded its sponsored research agreement with Virginia Commonwealth University…
CytoDyn reaches agreement with Albert Einstein Israelite Hospital in Brazil to conduct two COVID-19 trials
On May 5, 2021, CytoDyn announced an agreement to partner with the Albert Einstein Israelite Hospital (AEIH) in…
Moderna announced expansion of its manufacturing technology center in Massachusetts
On May 4, 2021, Moderna announced an expansion of the Moderna Technology Center (MTC) in Norwood, MA including…
Gavi signed agreement with Moderna to secure doses on behalf of COVAX Facility
On May 3, 2021, Gavi, the Vaccine Alliance, that it had signed an advance purchase agreement with Moderna…
Moderna announced supply agreement with Gavi for up to 500 million doses of COVID-19 Vaccine Moderna for COVAX
On May 3, 2021, Moderna announced an agreement with Gavi, the Vaccine Alliance to supply up to 500…
Novavax initiated pediatric expansion for phase 3 clinical trial of COVID-19 vaccine
On May 3, 2021, Novavax announced that it had initiated a pediatric expansion of its Phase 3 clinical…
Moderna announced Emergency Use listing granted by the WHO for its COVID-19 vaccine
On Apr. 30, 2021, Moderna announced that the World Health Organization (WHO) had issued Emergency Use Listing (EUL)…
Lonza and Moderna entered agreement to double drug substance production for COVID-19 vaccine in Visp
On Apr. 29, 2021, Lonza announced the expansion of its collaboration with Moderna to manufacture the drug substance…
Moderna announced an increased global supply for COVID-19 vaccine to up to 3 billion doses in 2022
On Apr. 29, 2021, Moderna announced it was making new funding commitments to increase supply at its owned…
CDC | COVID-19 | Infectious Disease | Vaccine
Fully vaccinated adults 65 and older are 94% less likely to be hospitalized with COVID-19
On Apr. 28, 2021, the Centers for Disease Control and Prevention (CDC) announced that both mRNA COVID-19 vaccines…
Biotechnology | COVID-19 | Disease | Infectious Disease | Oncology | Rare Disease | Therapeutics | Vaccine
Moderna announced agreement with Sanofi for manufacturing of Moderna COVID-19 Vaccine in the U.S.
On Apr. 26, 2021, Moderna announced that it had entered into an agreement with Sanofi for fill/finish sterile…
Moderna announced new COVID-19 vaccine supply agreement with Israel for 2022
On Apr. 20, 2021, Moderna announced a new supply agreement with Israel for 2022 whereby Israel also retained…
CytoDyn submitted Most Crucial Section of interim order to Health Canada for COVID-19 under rolling review
On Apr. 19, 2021, CytoDyn announced it had submitted the manufacturing section (CMC) of the application for an…
Broad Institute expanded COVID-19 viral sequencing efforts for variant surveillance in the Northeast
On Apr. 19, 2021, the Broad Institute of MIT in partnership with the Centers for Disease Control and…
Tonix Pharma entered worldwide licensing agreement to develop antiviral SARS-CoV-2 inhibitor for treatment of COVID-19
On Apr. 19, 2021, Tonix Pharmaceuticals and OyaGen announced an exclusive worldwide licensing agreement for an antiviral inhibitor…
Biotechnology | COVID-19 | Diagnostics | Genomics | Infectious Disease | Non-Profit Research | Therapeutics
Texas A&M lab identified new COVID-19 variant; genome suggested potential resistance to antibodies
On Apr. 19, 2021, scientists at the Texas A&M University Global Health Research Complex (GHRC) announced they had…
NIH funded new influenza research network
On Apr. 15, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had had established…
INOVIO’s COVID-19 vaccine candidate provided broad cross-reactive immune responses In humans against variants
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…